Malte - anglais - Medicines Authority

sanquin plesmanlaan 125, 1066 cx amsterdam, netherlands - human plasma, protein - solution for infusion - human plasma protein 40 g/l - blood substitutes and perfusion solutions

Australie - anglais - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium acetate, quantity: 1.28 g/l; sodium chloride, quantity: 2.34 g/l; magnesium acetate tetrahydrate, quantity: 320 mg/l; glucose, quantity: 50 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - plasma-lyte 56 and 5% glucose iv infusion is indicated as a source of water, electrolytes and calories or as an alkalinising agent. plasma-lyte 56 in 5% glucose is indicated as a source of water and electrolytes or as an alkalinising agent.

Irlande - anglais - HPRA (Health Products Regulatory Authority)

elanco animal health, eli lilly and company limited - mycoplasma hyopneumoniae strain p-5722-3 - emulsion for injection - unknown - mycoplasma vaccine - porcine - immunological

Irlande - anglais - HPRA (Health Products Regulatory Authority)

boehringer ingelheim ltd - mycoplasma hyopneumoniae, j strain, isolate b-3745, mycoplasma hyopneumoniae - emulsion for injection - 3.0x10^8 - 6.0*x10^8, 1:80 colour changing units/dose - mycoplasma - pigs - immunological - inactivated vaccine

Irlande - anglais - HPRA (Health Products Regulatory Authority)

elanco animal health, eli lilly and company limited - mycoplasma hyopneumoniae strain p-5722-3 - emulsion for injection - not currently available - mycoplasma - pigs - immunological

Irlande - anglais - HPRA (Health Products Regulatory Authority)

boehringer ingelheim vetmedica gmbh - mycoplasma hyopneumoniae, j strain, isolate b-3745; mycoplasma hyopneumoniae - emulsion for injection - . colour changing units/dose - mycoplasma

Australie - anglais - Department of Health (Therapeutic Goods Administration)

siemens healthcare pty ltd - ct820 - toxoplasma ivds - for in vitro diagnostic use in testing clinical specimens to provide information about the presence of, or infection with, the parasitic protozoan toxoplasma gondii.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

biomerieux australia pty ltd - ct820 - toxoplasma ivds - ivds intended to be used in testing to provide information about the presence of, or infection with the parasitic protozoan toxoplasma.

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioproperties pty. ltd. - mycoplasma gallisepticum strain ts-11 - misc. vaccines or anti sera - mycoplasma gallisepticum strain ts-11 vaccine-general active 0.0 ccu/dose - immunotherapy - poultry layers (eggs for human consump) | caged layers | chickens | chooks | hen - chronic respiratory disease | mycoplasma gallisepticum | vaccine | chronic respiratory disease (c | equine rotavirus | infectious sinusitis

Union européenne - anglais - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies).to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies.to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies).mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.